Kratom Safety and Withdrawal: Two Abstracts From One 15-Day Human Trial

Two reports, not two independent trials

A controlled human trial can provide useful evidence about kratom without settling whether its use is safe over longer periods. The two supplied abstracts describe single-dose exposure and 15 consecutive daily doses of dried kratom leaf powder, with one emphasizing safety and tolerability and the other abuse-related outcomes. Their shared participant counts, exposure groups and study design indicate reports from the same trial, rather than two independent confirmations of the findings. S1 S2

The study included 116 volunteers: 49 received kratom and 67 received placebo. It used a randomized, double-blind, placebo-controlled, dose-escalation design. Randomization and a placebo comparison strengthen interpretation compared with an uncontrolled account of use, but the total enrollment should not be mistaken for the number exposed to kratom. The active group was further divided into four cohorts, leaving only 12 or 13 participants in each exposure group. S1 S2

Only the abstracts are available in the supplied evidence; the full papers were not reviewed. That limits assessment of the detailed methods, individual laboratory results, outcome timing and statistical analyses. The safety abstract also describes follow-up using several time spans whose relationship is not fully clear from its summary. The clearest shared exposure window is 15 daily doses, not 47 days of continuous daily use. S1 S2

What the safety observations actually show

No serious adverse events or deaths were reported. That is an important observation within this trial, but it is narrower than a finding that kratom cannot cause serious harm. With 49 participants receiving the tested product and a short repeated-exposure period, the study cannot establish the absence of uncommon events or problems that emerge after longer use. Its results describe what was observed under these particular conditions. S1 S2

The safety abstract reports that treatment-emergent adverse events generally increased as exposure increased. After single administration, the most commonly reported events included dizziness, nausea and a feeling of relaxation. After repeated administration, common events included headache, feeling hot, increased alanine aminotransferase level and nausea. Thus, the authors' overall tolerability conclusion should not be read as meaning participants experienced no adverse events or laboratory changes. S1

The reported alanine aminotransferase increase deserves particular care in interpretation. The abstract identifies it among common events after repeated administration but does not provide the magnitude, participant-level pattern or detailed clinical assessment. It therefore supports saying that an increase was reported, not diagnosing liver injury or dismissing the finding as harmless. Abstract-only access leaves that distinction unresolved rather than supplying grounds for either a reassuring or an alarming conclusion. S1

Withdrawal and subjective effects were measured separately

The abuse-related report used the Drug Effects Questionnaire to assess subjective effects and two named withdrawal instruments: the Subjective Opioid Withdrawal Scale and the Clinical Opiate Withdrawal Scale. No participants met the threshold for clinically meaningful opioid withdrawal based on COWS or SOWS. This is a specific finding tied to those instruments and this exposure period, not proof that withdrawal is impossible after other patterns or durations of kratom use. S2

Subjective responses were generally dose-related, with an exception between the middle two exposure levels. Statistically significant increases relative to placebo in maximum effect and area-under-the-curve were reported only at the highest single exposure. Responses decreased following repeated administration. These questionnaire findings describe measured subjective responses; they do not establish therapeutic benefit, predict an individual experience or independently demonstrate that repeated use carries no dependence risk. S2

Abuse-related treatment-emergent adverse events occurred more often at higher exposures but were generally mild and resolved without sequelae, according to the abstract. The authors describe minimal withdrawal symptoms and modest subjective effects. Those observations help define the short-term study result, but the abstract does not present a comprehensive assessment of long-term patterns of use. Its conclusion supports further investigation rather than closing the question of abuse potential. S2

Why participants and product boundaries matter

The safety report restricted enrollment to healthy, nonsmoking adults aged 18–55 who had never used kratom or had not used it for at least 12 months. It also specified a body-mass-index range and excluded participants with certain known genetic polymorphisms involving CYP3A4, CYP2D6 or CYP1A2. Those criteria narrow the population represented. The findings cannot simply be extended to people with different health characteristics or established, ongoing kratom use. S1

Both abstracts concern a named dried-leaf product with stated mitragynine content, not a comparison across retail products. Product identity and alkaloid characterization help define what participants received, but these abstracts do not establish that another powder, an extract or an isolated alkaloid preparation would produce equivalent results. Nor do the supplied summaries provide a retail quality audit or sufficient testing documentation to evaluate contaminants in unrelated products. S1 S2

The most defensible reading is therefore bounded: one controlled human trial reported no serious adverse events or deaths, observed adverse events and subjective effects, and found no withdrawal scores meeting its clinically meaningful thresholds after the tested exposure. Two abstracts provide complementary views of that trial, not independent replication. Longer-term safety, broader population relevance and outcomes with other products remain outside what this abstract-only evidence can establish. S1 S2